Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia.
A new study conducted at the University College London, UK, found a new marker that has the capacity to help diagnose fatal breast cancer up to one year earlier than existing methods.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict are being featured at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas.
According to a latest study, several factors are responsible for the differences in the survival statistics of the non-elderly women with breast cancer. For example in 2012, the health reports had revealed that black women have a 43% higher risk of death when affected with breast cancer compared to their white counterparts.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
According to a research conducted at the University of Jyväskylä, estrogen acts as a regulator of muscle energy metabolism and muscle cell viability. Menopause leads to the cessation of ovarian estrogen production concurrent to the deterioration of muscle function.
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.
There has been much debate regarding the utility of prostate cancer screening in reducing the rates of deaths due to this cancer among men. While the ERSPC (European Randomized Study of Screening for Prostate Cancer) suggests that screening reduced prostate cancer deaths, the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found that regular screening does not reduce the cancer death rates in prostate cancer. Researchers thus looked at the actual picture as to which of these – ERSPC or PLCO are correct.
The Southeast's first comprehensive cancer treatment program at the University of Alabama at Birmingham takes patient care to the next level by improving the lives of women affected by or at risk for ovarian cancer.
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy.
New research indicates that dietary soy products are safe and even beneficial for women diagnosed with breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma, hormone maintenance therapy may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
Postmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study carried out at the University of Eastern Finland.
Taking one-fourth the standard dose of a widely used drug for prostate cancer with a low-fat breakfast can be as effective - and four times less expensive - as taking the standard dose as recommended: on an empty stomach.
Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous.
New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analyzing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and guide treatment decisions without compromising outcomes.
Building on earlier clinical trials, UCLA researchers have confirmed that the "breakthrough" drug palbociclib when used in combination with the traditional hormonal therapy letrozole delays progression of advanced breast cancer significantly and without the harsh side effects seen in some women prescribed letrozole alone.
Women who undergo hormone therapy for menopausal symptoms such as hot flashes can not only increase bone mass, but also can improve bone structure, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism.
The current method of treating prostate cancer involves identifying gene defects, which could help with the diagnosis of cancer and the development of individualised cancer treatments for patients.
Painful sex in women after cancer treatment is relatively common, often treatable and needs to be addressed by medical providers, a UC Davis oncologist and researcher suggests.